Sigma Systems Accelerates Product and Service Innovation for Hong Kong’s SmarTone
4.11.2019 06:00:00 EET | Business Wire | Press release
Sigma Systems, the global leader in catalog-driven software, today announces that it has been selected by SmarTone, a leading telecommunications provider with operating subsidiaries in Hong Kong and Macau, to accelerate its digital transformation and time-to-market for new products and offerings for its two million-plus customers.
Under this multi-year agreement, Sigma Systems will deploy Sigma Catalog, Sigma CPQ, Sigma Order Management, Sigma Portfolio Inventory and Sigma Insights, which constitute its award-winning Create-Sell-Deliver Portfolio. This will accelerate product and service innovation for SmarTone, expedite service delivery to customers and play a central role in supporting the service provider’s 5G-focused strategy. The implementation will be carried out in partnership with Hong Kong-headquartered WiseSpot, a leading systems integrator and solutions developer for the telecommunications industry.
Stephen Chau, Chief Technology Officer, SmarTone, commented: “Service excellence has always been our forte in setting us apart from our competition. At SmarTone, we strive to provide customers with an optimal user experience by continuously investing to improve our dynamic blend of key technologies and fine skills. With the advent of 5G, enhancing our core capability to more rapidly innovate around services will be vital in introducing new applications on IoT, mobile connectivity, edge computing and highly immersive, interactive experiences. By partnering with Sigma Systems, we will be better equipped to continue building our strength and serve our customers as their preferred service provider, as we look to roll out a new range products and services in line with our vision for a 5G future.”
Tim Spencer, Chief Executive Officer, Sigma Systems, commented: “In the age of digital services and 5G, driving product innovation and capitalizing upon new revenues is an imperative for CSPs. Today’s service providers need to create, sell and deliver services in a frictionless, automated and error-free way. At Sigma Systems, our strength lies in helping service providers successfully navigate complexities inherent in the current landscape and transform their businesses to accelerate product innovation – and get Next Done NowTM. This agreement with SmarTone is testament to the value that Sigma Systems’ Create-Sell-Deliver portfolio brings to any service provider and we are confident that with our unique offering, they will be able to launch new products and services seamlessly, and thus cater effectively to a new generation of consumers.”
For further information about Sigma Systems, its award-winning Create-Sell-Deliver portfolio, and getting Next Done NowTM visit sigma-systems.com, or contact us on info@sigma-systems.com.
About Sigma Systems (Twitter @SigmaSystems)
Sigma Systems is the global leader in catalog-driven software solutions for telecommunications, media and high-tech companies. It serves over 80 customers in 40 countries with its award-winning products. The company’s portfolio spans enterprise-wide Catalog, Configure Price Quote (CPQ), Order Management, Provisioning, Insights and Portfolio Inventory products, and offers a core set of services including professional services, cloud services, and managed services. Sigma utilizes an agile approach to implementing its B/OSS products for its customers. Sigma has offices in North and South America, Europe and the Asia Pacific region, with technology and integration partners around the globe. Sigma is a Hansen Technologies company publicly listed on the Australian Stock Exchange – ASX:HSN.
Additional information can be found online at https://sigma-systems.com/.
Visit Hansen Technologies at https://www.hansencx.com/.
About SmarTone
SmarTone Telecommunications Holdings Limited (0315.HK) is a leading telecommunications company with operating subsidiaries in Hong Kong and Macau, providing voice, multimedia and mobile broadband services, as well as fixed fibre broadband services for the consumer and corporate markets. Its goal is to deliver unbeatable and valuable experiences to customers through its powerful network, purposeful apps and passionate service. The company has been listed in Hong Kong since 1996. It is a subsidiary of Sun Hung Kai Properties Limited (0016.HK).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191103005007/en/
Contact information
Adnan Bashir
Senior Corporate Communications Manager
Sigma Systems
+1 647-204-0999
Chloe Purcell
Head of PR
Milner Strategic Marketing Ltd.
+44 1473 633123
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom